Reported Earnings • Aug 18
First quarter 2027 earnings released: JP¥5.20 loss per share (vs JP¥7.89 loss in 1Q 2026) First quarter 2027 results: JP¥5.20 loss per share (improved from JP¥7.89 loss in 1Q 2026). Revenue: JP¥215.4m (up JP¥190.6m from 1Q 2026). Net loss: JP¥134.2m (loss narrowed 34% from 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (JP¥200m revenue, or US$1.2m). Market cap is less than US$100m (JP¥7.04b market cap, or US$43.1m). Announcement • Jun 28
Tsubota Laboratory Incorporated to Report Q1, 2027 Results on Aug 12, 2026 Tsubota Laboratory Incorporated announced that they will report Q1, 2027 results on Aug 12, 2026 Announcement • Jun 19
Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe On June 17, 2026, Tsubota Laboratory Incorporated closed the transaction. Reported Earnings • May 19
Full year 2026 earnings released: JP¥29.55 loss per share (vs JP¥8.01 profit in FY 2025) Full year 2026 results: JP¥29.55 loss per share (down from JP¥8.01 profit in FY 2025). Revenue: JP¥200.0m (down 85% from FY 2025). Net loss: JP¥761.0m (down 471% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Announcement • May 14
Tsubota Laboratory Incorporated, Annual General Meeting, Jun 23, 2026 Tsubota Laboratory Incorporated, Annual General Meeting, Jun 23, 2026. Reported Earnings • Feb 16
Third quarter 2026 earnings released: JP¥7.25 loss per share (vs JP¥1.55 profit in 3Q 2025) Third quarter 2026 results: JP¥7.25 loss per share (down from JP¥1.55 profit in 3Q 2025). Revenue: JP¥43.0m (down 86% from 3Q 2025). Net loss: JP¥187.0m (down JP¥226.6m from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. New Risk • Dec 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (JP¥9.41b market cap, or US$59.8m). Announcement • Dec 12
Tsubota Laboratory Incorporated to Report Q3, 2026 Results on Feb 13, 2026 Tsubota Laboratory Incorporated announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Nov 14
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥8.54b market cap, or US$55.3m). Announcement • Sep 02
Tsubota Laboratory Incorporated to Report Q2, 2026 Results on Nov 11, 2025 Tsubota Laboratory Incorporated announced that they will report Q2, 2026 results on Nov 11, 2025 Reported Earnings • Aug 08
First quarter 2026 earnings released: JP¥7.87 loss per share (vs JP¥6.80 loss in 1Q 2025) First quarter 2026 results: JP¥7.87 loss per share (further deteriorated from JP¥6.80 loss in 1Q 2025). Revenue: JP¥24.0m (down 4.0% from 1Q 2025). Net loss: JP¥202.0m (loss widened 16% from 1Q 2025). Announcement • Jun 27
Tsubota Laboratory Incorporated to Report Q1, 2026 Results on Aug 13, 2025 Tsubota Laboratory Incorporated announced that they will report Q1, 2026 results on Aug 13, 2025 Reported Earnings • May 14
Full year 2025 earnings released: EPS: JP¥8.01 (vs JP¥25.14 loss in FY 2024) Full year 2025 results: EPS: JP¥8.01 (up from JP¥25.14 loss in FY 2024). Revenue: JP¥1.36b (up 102% from FY 2024). Net income: JP¥205.0m (up JP¥846.0m from FY 2024). Profit margin: 15% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue. Announcement • May 12
Tsubota Laboratory Incorporated, Annual General Meeting, Jun 25, 2025 Tsubota Laboratory Incorporated, Annual General Meeting, Jun 25, 2025. New Risk • Apr 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (JP¥9.28b market cap, or US$63.7m). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to JP¥310, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in Japan. Total loss to shareholders of 8.6% over the past year. Announcement • Mar 27
Tsubota Laboratory Incorporated to Report Fiscal Year 2025 Results on May 12, 2025 Tsubota Laboratory Incorporated announced that they will report fiscal year 2025 results on May 12, 2025 Announcement • Feb 17
Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 Tsubota Laboratory Incorporated Revised earnings guidance for the fiscal year ending March 31, 2025. The company announced that Operating results for the first three quarters under review made steady progress, including the conclusion of a licensing agreement with a Chinese company. On the other hand, the weaker-than-expected trend of the yen against the U.S. dollar and other currencies resulted in the accrual of foreign exchange gains of approximately JPY 30 million. As for the full-year earnings forecast announced on May 13, 2024, ordinary income is expected to increase 23.1% (JPY 30 million) from the previously announced forecast to JPY 160 million. As a result of the above, net income for the fiscal year ending March 2025 is expected to be JPY 110 million, an increase of 10% (JPY 10 million) from the previously announced forecast. the company expects net sales to be JPY 1,200 million. Operating profit to be JPY 131 million. Basic earnings per share to be JPY 4.29. Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: JP¥1.56 (vs JP¥25.90 loss in 3Q 2024) Third quarter 2025 results: EPS: JP¥1.56 (up from JP¥25.90 loss in 3Q 2024). Revenue: JP¥306.0m (up 145% from 3Q 2024). Net income: JP¥40.0m (up JP¥702.0m from 3Q 2024). Profit margin: 13% (up from net loss in 3Q 2024). The move to profitability was primarily driven by higher revenue. Announcement • Dec 10
Tsubota Laboratory Incorporated to Report Q3, 2025 Results on Feb 12, 2025 Tsubota Laboratory Incorporated announced that they will report Q3, 2025 results on Feb 12, 2025 Announcement • Nov 20
Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 Tsubota Laboratory Incorporated provided earnings guidance for the fiscal year ending March 31, 2025. For the year, the company expects net sales to be JPY 1,200 million. Operating profit to be JPY 131 million. Profit to be JPY 100 million. Basic earnings per share to be JPY 3.91. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: JP¥8.52 (vs JP¥6.62 loss in 2Q 2024) Second quarter 2025 results: EPS: JP¥8.52 (up from JP¥6.62 loss in 2Q 2024). Revenue: JP¥461.0m (up JP¥436.0m from 2Q 2024). Net income: JP¥218.0m (up JP¥387.0m from 2Q 2024). Profit margin: 47% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Announcement • Aug 27
Tsubota Laboratory Incorporated to Report Q2, 2025 Results on Nov 12, 2024 Tsubota Laboratory Incorporated announced that they will report Q2, 2025 results on Nov 12, 2024 Announcement • Jun 06
Tsubota Laboratory Incorporated to Report Q1, 2025 Results on Aug 13, 2024 Tsubota Laboratory Incorporated announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • May 16
Full year 2024 earnings released: JP¥25.14 loss per share (vs JP¥3.66 profit in FY 2023) Full year 2024 results: JP¥25.14 loss per share (down from JP¥3.66 profit in FY 2023). Revenue: JP¥673.0m (down 30% from FY 2023). Net loss: JP¥641.0m (down JP¥731.0m from profit in FY 2023). Announcement • May 15
Tsubota Laboratory Incorporated, Annual General Meeting, Jun 26, 2024 Tsubota Laboratory Incorporated, Annual General Meeting, Jun 26, 2024. Announcement • Mar 02
Tsubota Laboratory Incorporated to Report Fiscal Year 2024 Results on May 10, 2024 Tsubota Laboratory Incorporated announced that they will report fiscal year 2024 results on May 10, 2024 Reported Earnings • Feb 16
Third quarter 2024 earnings released: JP¥25.90 loss per share (vs JP¥5.05 profit in 3Q 2023) Third quarter 2024 results: JP¥25.90 loss per share (down from JP¥5.05 profit in 3Q 2023). Revenue: JP¥125.0m (down 62% from 3Q 2023). Net loss: JP¥662.0m (down JP¥789.0m from profit in 3Q 2023). New Risk • Feb 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.7% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Revenue is less than US$5m (JP¥448m revenue, or US$3.0m). Market cap is less than US$100m (JP¥6.90b market cap, or US$46.2m). Reported Earnings • Nov 13
Second quarter 2024 earnings released: JP¥6.62 loss per share (vs JP¥5.05 profit in 2Q 2023) Second quarter 2024 results: JP¥6.62 loss per share (down from JP¥5.05 profit in 2Q 2023). Revenue: JP¥25.0m (down 92% from 2Q 2023). Net loss: JP¥169.0m (down 233% from profit in 2Q 2023). Reported Earnings • Aug 12
First quarter 2024 earnings released: JP¥4.90 loss per share (vs JP¥2.74 loss in 1Q 2023) First quarter 2024 results: JP¥4.90 loss per share (further deteriorated from JP¥2.74 loss in 1Q 2023). Revenue: JP¥24.0m (down 73% from 1Q 2023). Net loss: JP¥124.0m (loss widened 100% from 1Q 2023). Announcement • Jun 28
Tsubota Laboratory Incorporated to Report Q1, 2024 Results on Aug 10, 2023 Tsubota Laboratory Incorporated announced that they will report Q1, 2024 results on Aug 10, 2023 Announcement • Dec 04
Tsubota Laboratory Incorporated to Report Q3, 2023 Results on Feb 10, 2023 Tsubota Laboratory Incorporated announced that they will report Q3, 2023 results on Feb 10, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 28
Tsubota Laboratory Incorporated to Report Q2, 2023 Results on Nov 10, 2022 Tsubota Laboratory Incorporated announced that they will report Q2, 2023 results on Nov 10, 2022 Announcement • Jun 29
Tsubota Laboratory Incorporated to Report Q1, 2023 Results on Aug 12, 2022 Tsubota Laboratory Incorporated announced that they will report Q1, 2023 results on Aug 12, 2022 Announcement • Jun 23
Tsubota Laboratory Incorporated has completed an IPO in the amount of ¥1.8048 billion. Tsubota Laboratory Incorporated has completed an IPO in the amount of ¥1.8048 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,840,000
Price\Range: ¥470
Transaction Features: Sponsor Backed Offering 
